We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Htp5.5
5-HTP Research
Likely helps
54 peer-reviewed studies
What the evidence says
Likely helps
5-HTP appears to help in 5 of 5 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1983–2026 with a typical study size of 18 participants.
Based on 54 studies · 2 meta-analyses · 41 RCTs · 4,864 total participants
Sleep & insomniaMay improve sleep quality through serotonin/melatonin pathway · 1-2 weeks · Improved sleep quality via serotonin-to-melatonin conversion · 2-4 weeks · Modest improvement in sleep maintenance through serotonin support · 2-4 weeks
Mostly mechanism / observational5 studies
Migraine & headache
Mostly mechanism / observational4 studies
Weight management
Mostly mechanism / observational4 studies
Women's health
Mostly mechanism / observational4 studies
Cognitive function
Mostly mechanism / observational3 studies
By the numbers
Pulled from 17 studies with measurable effects
Likely real effects
75%
across studies
People studied
4,864
typical study: 18 people
Strongest designs
43
2 pooled, 41 randomised
Showed benefit
100%
5/5 studies
How long studies ran
1–3 months
3
Populations Studied
Healthy subjects2
Universal PTSD prevention populations1
Adults with fibromyalgia1
Review1
Steady research
10 studies in the last 5 years · Latest meta-analysis: 2020
198320042026
1Systematic Reviewn=2,023 · very large study2022
In plain English: This review provides uncertain evidence only regarding the use of hydrocortisone, propranolol, dexamethasone, omega-3 fatty acids, gabapentin, paroxetine, PulmoCare formula, Oxepa formula, or 5-hydroxytryptophan as universal PTSD prevention strategies.
Bertolini F et al. · The Cochrane database of systematic reviews (2022)
This review provides uncertain evidence only regarding the use of hydrocortisone, propranolol, dexamethasone, omega-3 fatty acids, gabapentin, paroxetine, PulmoCare formula, Oxepa formula, or 5-hydroxytryptophan as universal PTSD prevention strategies.
Future research might benefit from larger samples, better reporting of side effects and inclusion of quality of life and functioning measures.
In plain English: There are few, large, high-quality trials comparing combination pharmacotherapy with monotherapy for fibromyalgia, consequently limiting evidence to support or refute the use of combination pharmacotherapy for fibromyalgia.
Thorpe J et al. · The Cochrane database of systematic reviews (2018)
Two studies only reported any primary outcomes of interest (patient-reported pain relief of 30%, or 50%, or greater).
There are few, large, high-quality trials comparing combination pharmacotherapy with monotherapy for fibromyalgia, consequently limiting evidence to support or refute the use of combination pharmacotherapy for fibromyalgia.
4Narrative review of 5-HTP physiology and clinical useReview2020
In plain English: The physiological role of 5-HTP in the treatment of depression, anxiety, panic, sleep disorders, obesity, myoclonus and serotonin syndrome are also discussed.
Maffei ME · International journal of molecular sciences (2020)
Decarboxylation of 5-HTP yields serotonin (5-hydroxytryptamine, 5-HT) that is further transformed to melatonin (N-acetyl-5-methoxytryptamine).
5-HTP plays a major role both in neurologic and metabolic diseases and its synthesis from tryptophan represents the limiting step in serotonin and melatonin biosynthesis.
5-HTP toxicity and the occurrence of toxic impurities present in tryptophan and 5-HTP preparations are also discussed.
5Alcohol use disorder treatment effectivenessSystematic Review2018
In plain English: No significant benefit for the use of combinations over single agents was observed.
Naglich AC et al. · CNS drugs (2018)
Drug combination effect sizes were comparable to those observed in single-agent trials.
No significant benefit for the use of combinations over single agents was observed.
However, benefit may be observed when combined pharmacological interventions address specific symptoms of alcohol use disorder known to be influenced by combination components, or when combinations are used in specific subpopulations in which combination components demonstrate benefit.
13Cognitive function (MoCA score)RCTn=30 · small study2025
In plain English: However, given the relatively small sample size (n = 30) and short-term (12-week) intervention, these findings should be interpreted cautiously, and further long-term studies with a larger sample size are warranted to confirm these preliminary results.
Li S et al. · Nutrients (2025)
Noticeable benefit
← WorseNo effectBetter →
Borderline
Results: A significant time effect was observed in the MoCA score, which was mainly explained by a significant increase in the 5-HTP group (week 0 vs. week 12: 26.6 ± 1.4 a.u. vs. 27.6 ± 1.4 a.u., p < 0.05).
Moreover, the 5-HTP group showed a significant increase in serum serotonin levels.
Additionally, the GDS score improved in the 5-HTP group (week 0 vs. week 8: 1.2 ± 1.7 a.u. vs. 0.7 ± 1.2 a.u., p < 0.05).